{
  "docId": "019dd923-5ca1-7489-b636-bc879d1b6d64",
  "docSlug": "17680cec2cbd3510",
  "documentTitle": "Accelerated Access Review UK Mapping",
  "authorId": "Deloitte",
  "authorName": "Deloitte",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 83,
  "pageCount": 109,
  "prevPage": 82,
  "nextPage": 84,
  "slideType": "pain_points",
  "function": "diagnose",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a list-based structure to detail specific systemic barriers in the UK healthcare reimbursement landscape.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "icon_grid"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b636-bc879d1b6d64/83",
  "deckHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64#slide-83",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.05,
        "y": 0.59
      },
      "kind": "list",
      "text": "System requires Industry push: Suggestion that Industry (especially SMEs) are unwilling to engage with NICE at early dialogue opportunities or submit products for assessment due to concerns about success rates.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08e069ec-4a1a-4c9d-be14-d3354d49e832",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Lack of funding mandate: In vitro diagnostics recommended by the DAP do not receive a funding mandate, with limited effect on local adoption. Where a drug and its CDx is recommended through the NICE TAP, there is no funding mandate for the CDx.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e6e11a0-ef55-4abf-8c8a-3ba705ec605f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.05,
        "y": 0.76
      },
      "kind": "list",
      "text": "Usual funding streams don't cover CDx: Currently, pharmaceutical companies pay for a considerable proportion of companion diagnostic tests due to uncertainties around the funding of companion diagnostics by the NHS.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b22fcac-2aea-4a3e-8b2b-d4b50e3b454e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.05,
        "y": 0.42
      },
      "kind": "list",
      "text": "Lack of commercialisation capability: Manufacturers, especially SMEs, and healthcare professionals sometimes struggle to articulate and measure the value proposition of in vitro diagnostics.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8c27a26-3538-48a3-9a12-be53263e2d08",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.11
      },
      "kind": "paragraph",
      "text": "Our research highlighted four key challenges in the national reimbursement and commissioning stage for the early access to innovative in vitro diagnostics",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a18489b-c812-4a7e-b11b-d80acb5e7fba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.55,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Notes: CDx = co-diagnostics; TAP = Technology Appraisal Programme; DAP = Diagnostics Assessment Programme. Source: Stakeholder interviews, workshops and Deloitte analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55d655b5-7d54-477d-afd0-fb785b9c4cf3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.25,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Key Challenges",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e20b1c62-5878-455d-929a-60ed2172ebc3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "04136d08-ca4f-40d7-b72c-7ca5a03b2b98",
      "evidence": "list/bullet: Lack of funding mandate: In vitro diagnostics recommended by the DAP do not receive a funding mandate, with limited effect on local adoption. Where a drug and its CDx is recommended through the NICE TAP, the",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 109,
      "from": 21,
      "beatId": "4bae8ed9-97e4-4ca8-988f-171e64b0598d",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document proposes solutions to address the challenges, including streamlining development pathways and improving regulation.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 109,
      "from": 21,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "575c67ea-abbb-4bd3-80bc-943f97973ed4",
      "evidence": "The document proposes solutions to address the challenges, including streamlining development pathways and improving regulation.",
      "position": 1,
      "objective": "How can the NHS improve access to medical innovations?",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.7,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}